The Role of 11β-Hydroxysteroid Dehydrogenases in the Cardiovascular System

Endocrine Journal

Volumn 50, Issue 5, 2003, Pages 485-489

  Krozowski, Zygmunt ^a   Chai, Zhonglin ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CALCIUM; CARBENOXOLONE; COLLAGEN TYPE 1; CORTICOSTERONE; CORTISONE; DEHYDROCORTICOSTERONE; ENDOTHELIN 1; GLUCOCORTICOID; GLUCOSE; GLYCOPROTEIN; GLYCYRRHETINIC ACID; HYDROCORTISONE; INTERLEUKIN 1BETA; KAINIC ACID; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOLIPASE A2; PROGESTERONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RENIN; SODIUM; STEROID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; ISOENZYME;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; BLOOD PRESSURE MONITORING; BLOOD VESSEL REACTIVITY; BRAIN LEVEL; CALCIUM URINE LEVEL; CARDIOVASCULAR SYSTEM; CHROMOSOME 16Q; CORTICOSTERONE BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SYNTHESIS; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCOGENOLYSIS; HIPPOCAMPUS; HORMONE METABOLISM; HUMAN; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; ION TRANSPORT; KIDNEY DISTAL TUBULE; KNOCKOUT MOUSE; LEARNING DISORDER; LIPOLYSIS; MAZE TEST; MEMORY; MOLECULAR SIZE; MUTATIONAL ANALYSIS; NERVE CELL LESION; NONHUMAN; OBESITY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; PROTEIN DOMAIN; PROTEIN MOTIF; RECEPTOR AFFINITY; REVIEW; STRESS; THREE DIMENSIONAL IMAGING; TISSUE DIFFERENTIATION; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CARDIOVASCULAR FUNCTION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; CARDIOVASCULAR PHYSIOLOGY; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; ISOENZYMES; OBESITY; TISSUE DISTRIBUTION;

EID: 0344873291     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.50.485     Document Type: Review

References (37)

1. Stewart PM, Krozowski ZS (1999) 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 57: 249-324.
2. Krozowski Z (1994) The short-chain alcohol dehydrogenase superfamily: Variations on a common theme. J Steroid Biochem Mol Biol 51: 125-130.
3. Agarwal AK, Mune T, Monder C, White PC (1995) Mutations in putative glycosylation sites of rat 11 beta-hydroxysteroid dehydrogenase affect enzymatic activity. Biochim Biophys Acta 1248: 70-74.
4. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CRW, Seckl JR, Mullins JJ (1997) 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94: 14924-14929.
5. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR (2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11 {beta}-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 23: 23.
6. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev 19: 269-301.
7. Gomez-Sanchez EP, Gomez-Sanchez CE (1992) Central Hypertensinogenic Effects of Glycyrrhizic Acid and Carbenoxolone. Am J Physiol 263: E1125-E1130.
8. Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, Mullins JJ, Seckl JR (2001) Lack of tissue glucocorticoid reactivation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA 98: 4716-4721.
9. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC (2001) Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice. Endocrinology 142: 114-120.
10. Ajilore OA, Sapolsky RM (1999) In vivo characterization of 11beta-hydroxysteroid dehydrogenase in rat hippocampus using glucocorticoid neuroendangerment as an endpoint. Neuroendocrinology 69: 138-144.
11. Rajan V, Edwards CRW, Seckl JR (1996) 11 beta-hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci 16: 65-70.
12. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS (2001) A Transgenic Model of Visceral Obesity and the Metabolic Syndrome. Science 294: 2166-2170.
13. Andrews RC, Rooyackers O, Walker BR (2003) Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88: 285-291.
14. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R (2001) Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276: 12629-12635.
15. Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, Gustafsson JA (2002) Liver x receptors down-regulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 51: 2426-2433.
16. Bujalska IJ, Walker EA, Hewison M, Stewart PM (2002) A Switch in Dehydrogenase to Reductase Activity of 11beta-Hydroxysteroid Dehydrogenase Type 1 upon Differentiation of Human Omental Adipose Stromal Cells. J Clin Endocrinol Metab 87: 1205-1210.
17. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH (1999) Cortisol metabolism in human obesity: impaired cortisone → cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84: 1022-1027.
18. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ (1997) Tumor necrosis factor alpha and interleukin 1 beta enhance the cortisone/cortisol shuttle. J Exp Med 186: 189-198.
19. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM (2000) Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone 27: 375-381.
20. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17: 979-986.
21. Ferrari P, Bianchetti MG, Sansonnens A, Frey FJ (2002) Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2. J Am Soc Nephrol 13: 2540-2546.
22. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS (1994) Cloning and tissue distribution of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105: R11-R17.
23. Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585.
24. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghyazar M, Harbison MD, Wei JQ, Shackleton C, Funder JW, New MI (1995) A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 2263-2266.
25. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC (1995) Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 10: 394-399.
26. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ (1999) Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 103: 683-689.
27. Lifton RP, Gharavi AG, Geller DS (2001) Molecular mechanisms of human hypertension. Cell 104: 545-556.
28. Agarwal AK, Mune T, Monder C, White PC (1994) NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase - Cloning and characterization of cDNA from sheep kidney. J Biol Chem 269: 25959-25962.
29. Brereton PS, van Driel RR, Suhaimi F, Koyama K, Dilley R, Krozowski Z (2001) Light and electron microscopy localization of the 11beta-hydroxysteroid dehydrogenase type I enzyme in the rat. Endocrinology 142: 1644-1651.
30. Mazzocchi G, Rossi GP, Neri G, Malendowicz LK, Albertin G, Nussdorfer GG (1998) 11beta-hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. Faseb J 12: 1533-1539.
31. Mazzocchi G, Malendowicz LK, Aragona F, Tortorella C, Gottardo L, Nussdorfer GG (2002) 11beta-Hydroxysteroid dehydrogenase types 1 and 2 are up- and down-regulated in cortisol-secreting adrenal adenomas. J Investig Med 50: 288-292.
32. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ (2001) Reduced activity of 11beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 108: 1299-1305.
33. Edwards C, Benediktsson R, Lindsay RS, Seckl JR (1993) Dysfunction of Placental Glucocorticoid Barrier - Link Between Fetal Environment and Adult Hypertension. Lancet 341: 355-357.
34. Ruschitzka F, Quaschning T, Noll G, deGottardi A, Rossier MF, Enseleit F, Hurlimann D, Luscher TF, Shaw SG (2001) Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 103: 3129-3135.
35. Walker BR, Stewart PM, Shackleton C, Padfield PL, Edwards C (1993) Deficient Inactivation of Cortisol by 11-beta-Hydroxysteroid Dehydrogenase in Essential Hypertension. Clin Endocrinol 39: 221-227.
36. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R (1995) Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension 25: 67-70.
37. Takeda Y, Miyamori I, Iki K, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Takeda R (1996) Endogenous renal 11 beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 27: 197-201.